Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tlc Therapeutics LLC maintains 1 pending office action in the Biotechnology & Pharmaceuticals sector. Prosecution is currently concentrated under 1 distinct examiner and a distinct art unit. This indicates that the company's current patent strategy is highly focused, with no current diversification of its pending matters across different examiners or units. Such a concentrated workload allows for a very specific prosecution focus but lacks the broader exposure to different examiner perspectives that a larger portfolio might provide to the applicant.
AZPURU, CARLOS A is the busiest examiner for this portfolio. This examiner is currently overseeing the 1 pending office action associated with the company. Because there is a distinct examiner involved in the current workload, the company's immediate prosecution success in this technology area is tied to the findings of the assigned individual. The presence of a distinct art unit further suggests that the pending subject matter falls within a narrow technical niche within the broader biotechnology field. This concentration simplifies the management of the pending office action by limiting the number of points of contact at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18753210 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18753210 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18753210 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | AZPURU, CARLOS A | 1617 | §112DP | Non-Final OA | — | Pending | Jun 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTlc Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Carlos A Azpuru has the most, with 1 of Tlc Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
